New On-Demand Webcast Coming Soon.  

We are excited to share that the joint program of the IEC and IPC, Psoriasis or Dermatitis? When Boundaries Blur and Treatments Flip the Script, from AAD 2026 Global Education Day, will be available for on‑demand viewing soon.

Please keep an eye on our social media channels for the final posting announcement and viewing details.

Explore previously recorded IEC webcasts

Read the latest IEC publication by IEC Councilor Joseph F. Merola, Beth A. Childs, Brooke R. Bartley, along with IEC Directors and Councilors, published online in JAMA Dermatology.

International Eczema Council Definitions of Low Disease Activity and Remission in Atopic Dermatitis: A Consensus Statement. Joseph F. Merola, Beth A. Childs, Brooke R. Bartley, Robert Bissonnette, Thomas Bieber, Emma Guttman-Yassky, Amy S. Paller, Eric L. Simpson, April W. Armstrong, Alan D. Irvine. JAMA Dermatol. Published online April 15, 2026. doi:10.1001/jamadermatol.2026.0662

For all IEC publications, please see our expanded list.

The International Eczema Council continues to grow.

The IEC Board of Directors is proud to announce the following new members were approved at the March 2026 Board of Directors meeting.

March 2026

New Councilors:

• Perpetua Uchechi Ibekwe, PhD MBBS FMCP FWACP, Nigeria
• Emmanuella Guenova, PhD MD MSc, Austria

New Associates:

• Gianluca Avallone, MD, Italy
• Shamir Geller, MD, United States
• Hazel H. Oon, MD, Singapore
• Pedro J. Gomez-Arias, MD, Spain

Learn more about how you can become a councilor or associate.

Meet the Councilor Luis F. Santamaria-Babí, PhD | December 2025

We invite you to "Meet the Councilors and Associates". Get a personal glimpse into the mindsets of the IEC’s leading experts and key opinion leaders in the field who are solving complex dermatological challenges and navigating evolving field opportunities in atopic dermatitis and beyond.

Click here to learn more about IEC Councilor Luis F. Santamaria-Babí, PhD, full professor of clinical and translational immunology at the University of Barcelona, Spain, where he directs a research group at the Barcelona Science Park focused on human translational immunology in chronic inflammatory skin diseases.

Check out the 2025 4th Quarter e-News!

Learn more and explore the latest edition here or view the e-News archives.

Exploring JAK Inhibitors for Atopic Dermatitis
Not all JAKs are the same: Learn how JAKs can help your patients

Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease that significantly impacts quality of life for millions of patients. Recent advances in systemic therapies, including JAK inhibitors, offer new opportunities to address unmet needs in moderate-to-severe AD. Understanding the efficacy and safety profiles of these agents is essential for optimizing treatment strategies and improving patient outcomes.

Learn More